Managing the patient with newly diagnosed Parkinson disease

Cleveland Clinic Journal of Medicine

Volumn 79, Issue SUPPL.2, 2012, Pages

  Singer, Carlos ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA;

BRAIN DEPTH STIMULATION; HUMAN; KINESIOTHERAPY; PARKINSON DISEASE; REVIEW;

ANTIPARKINSON AGENTS; DEEP BRAIN STIMULATION; EXERCISE THERAPY; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 84868320531     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.79.s2a.01     Document Type: Article

References (22)

1. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351:2498-2508.
2. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayedstart trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361:1268-1278.
3. Pålhagen S, Heinonen E, Hägglund J, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006; 66:1200-1206.
4. Barbeau A, Mars H, Botez MI, Joubert M. Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a doubleblind cross-over study. Can Med Assoc J 1971; 105:42-46.
5. Hauser RA, Schapira AH, Rascol O, et al. Randomized, doubleblind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord 2010; 25:2542-2549.
6. Onofrj M, Bonanni L, De Angelis MV, Anzellotti F, Ciccocioppo F, Thomas A. Long half-life and prolonged-release dopamine receptor antagonists: a review of ropinirole prolonged-release studies. Parkinsonism Relat Disord 2009; 15(suppl 4):S85-S92.
7. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287:1653-1661.
8. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54:93-101.
9. Reichmann H. Transdermal delivery of dopamine receptor agonists. Parkinsonism Relat Disord 2009; 15(suppl 4):S93-S96.
10. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003; 60:1721-1728.
11. Watts RL, Jankovic J, Waters C et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007; 68: 272-276.
12. Bronzova J, Sampaio C, Hauser RA, et al. Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Mov Disord 2010; 25:738-746.
13. Stocchi F, Arnold G, Onofrj M, et al; Safinamide Parkinson's Study Group. Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004; 63:746-748.
14. Schapira AHV. Safinamide in the treatment of Parkinson's disease. Expert Opin Pharmacother 2010; 11:2261-2268.
15. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006; 66:664-671.
16. Shults CW, Oakes D, Kieburtz K; and the Parkinson Study Group. Effects of coenzyme q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002; 59:1541-1550.
17. Storch A, Jost W, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme q(10) in Parkinson disease. Arch Neurol 2007; 64:938-944.
18. Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010; 74:995-1002.
19. Samii A, Etminan M, Wiens MO, Jafari S. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging 2009; 26:769-779.
20. Ascherio A, LeWitt PA, Xu K, et al; Parkinson Study Group DATATOP Investigators. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol 2009; 66:1460-1468.
21. Espay AJ, Vaughan JE, Marras C, Fowler R, Eckman MH. Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson's disease: a decision analysis. Mov Disord 2010; 25:1456-1463.
22. Marks WJ Jr, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neur 2010; 9:1164-1172.